May 11 (Reuters) - Bristol-myers Squibb Co
* European Commission Approves The First And Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, For Treatment Of Advanced Melanoma
* Bristol Myers Squibb Co - Opdivo + Yervoy Regimen Now Approved For Unresectable Or Metastatic Melanoma Patients, Regardless Of Braf Mutational Status Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.